Overview
- The key Indian patent on semaglutide lapses on March 20, clearing the way for an immediate wave of more than 40–50 branded generics to launch as early as March 21.
- Prices are forecast to drop roughly 40–80% from current levels, with initial monthly costs widely reported in the ₹3,000–₹5,000 range.
- India’s CDSCO has cautioned against self-administration and influencer marketing, flagged these prescription drugs as Schedule G, and required Risk Management Plans and clear patient information for new launches.
- Hospitals, clinics and telehealth platforms are scaling obesity and diabetes programs, as drugmakers line up day‑one rollouts and partnerships, including Zydus granting Lupin semi‑exclusive co‑marketing rights with a reusable pen device.
- Safety scrutiny has intensified after a recent FDA warning letter to Novo Nordisk on post‑marketing reporting and a U.S. lawsuit alleging a death linked to Ozempic, with experts urging strong pharmacovigilance and clinician education during the rollout.